Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial

BACKGROUND: The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected specimens are seen in only a minority (28–38%) of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickhoff, Chris, Senan, Suresh, Schneiders, Famke L., Veltman, Joris, Hashemi, Sayed, Daniels, Johannes M. A., Fransen, Marieke, Heineman, David J., Radonic, Teodora, van de Ven, Peter M., Bartelink, Imke H., Meijboom, Lilian J., Garcia-Vallejo, Juan J., Oprea-Lager, Daniela E., de Gruijl, Tanja D., Bahce, Idris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427738/
https://www.ncbi.nlm.nih.gov/pubmed/32795284
http://dx.doi.org/10.1186/s12885-020-07263-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7427738/
https://www.ncbi.nlm.nih.gov/pubmed/32795284
http://dx.doi.org/10.1186/s12885-020-07263-9

Ejemplares similares